CDC updates guidance on Latent Tuberculosis treatment
Centre for disease control and prevention (CDC) has released guidance for the Treatment of Latent Tuberculosis Infection. This is an update on Comprehensive guidelines for the treatment of latent tuberculosis infection (LTBI) published in 2000.
These updated guidelines can be used by clinicians, public health officials, policymakers, health care organizations, and other state and local stakeholders who might need to adapt them to fit individual clinical circumstances.
The guidelines have been published in MMWR Recommendations and Reports. and they apply only to patients infected with Mycobacterium tuberculosis that is believed susceptible to INH or rifampin. These updated guidelines do not apply when evidence is available that the infecting M. tuberculosis strain is resistant to both isoniazid and rifampin
Shorter regimens are preferred over longer-course isoniazid (INH) monotherapy for treating latent tuberculosis, according to new guidelines from the National Tuberculosis Controllers Association and the CDC. Evidence shows that shorter rifamycin-based regimens are similarly effective to INH monotherapy but have less hepatotoxicity and better completion rates.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.